CDK4 status testing reveals discriminable protein profiles for sarcomas and also for histotypes renal clear cell carcinoma, lung adenocarcinoma, breast cancer, ovarian carcinoma, thyroid carcinoma, low-grade glioma, adrenocortical carcinoma, and lung squamous cell carcinoma (all not yet reported by OncoKB). This evidence concerns the gene CDK4 and clear cell renal carcinoma.